BPC-157 vs Cartalax
How BPC-157 and Cartalax compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
BPC-157 and Cartalax come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
BPC-157 vs Cartalax, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | BPC-157 | Cartalax |
|---|---|---|
| What it is | Synthetic pentadecapeptide (15 amino acids); often described as a gastric-protein fragment, although FDA found the proposed parent protein has not been independently characterized | Synthetic tripeptide and short peptide bioregulator marketed for cartilage and joint research |
| Class / category | Healing / recovery | Healing / recovery |
| Evidence tier | Animal-only · Unclear | In-vitro · Unclear · none in humans |
| Studied / approved for | Tendon and ligament healing; Gut/GI healing; Muscle and wound repair | Mesenchymal stem-cell aging in cell culture; Cartilage and joint repair claims based on preclinical rationale |
| US regulatory status (2026) | research use only (as of Jul 2026) | research use only (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | 2 | No data |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | Unknown |
| Key risks | Human safety data remain limited. A 2025 pilot reported no measured adverse effects after intravenous BPC-157 in two adults, but two previously exposed participants followed for days cannot establish a safe dose or long-term safety. Most safety information still comes from animal studies. | Cartalax has no established human adverse-event rate, safe dose, pharmacokinetic profile, interaction data, reproductive-safety record, or long-term safety trial. Cell-culture findings cannot establish human tolerability. Conflicting sequence claims in the research market add a separate product-identity risk. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
BPC-157 vs Cartalax: the two molecules
The 2D chemical structures, straight from PubChem — a quick way to see how similar (or not) the two actually are.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
If you want the option with more human evidence behind it
Leans toward BPC-157
BPC-157's evidence sits at animal-only, a more human tier than Cartalax's in-vitro. That reflects how the data was gathered, not a guarantee it works.
References
- 1.BPC-157 — indexed research (PubMed, National Library of Medicine)
- 2.BPC-157 — registered clinical studies (ClinicalTrials.gov)
- 3.FDA — compounding risk information on certain substances
- 4.BPC-157 compound record (PubChem CID 9941957)
- 5.Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review
- 6.Phase I Bepecin safety and pharmacokinetics trial (NCT02637284)